Public Market Listing
4578TSE
Live quotes, historical charts, and market capitalization for Otsuka Holdings are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(12 total)
12Total Assets
8Approved
2Phase 3 / Filed
2Phase 1–2 / Early
9Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist) · Dopamine D2/D3 and serotonin 5-HT1A receptor · Dopamine D2 receptor (partial agonist)Small molecule | Schizophrenia | |
| Approved | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist)Combination | Schizophrenia | |
| Approved | Dopamine D2/D3 and serotonin 5-HT1A receptorSmall molecule | Schizophrenia | |
| Approved | Decitabine/cedazuridine fixed combination (DNMT + CDA inhibition)Small molecule | Acute Myeloid Leukemia | |
| Approved | Dopamine D2/D3 and serotonin 5-HT1A receptorSmall molecule | Alzheimer's DiseaseMajor Depressive DisorderSchizophrenia | |
difamilast(Moizerto / Adquey) | Approved | PDE4Small molecule | Atopic Dermatitis |
Opicapone(Ongentys) | Approved | COMT · PDE4Small molecule | Parkinson's Disease |
Tolvaptan(Samsca / Jinarc) | Approved | Vasopressin V2 receptorSmall molecule | Heart FailureChronic Kidney Disease |
OPC-61815No recent activity | Phase 3 | Vasopressin V2 receptorSmall molecule | Heart Failure |
| Phase 3 | TAAR1 (trace amine-associated receptor 1)Small molecule | Schizophrenia | |
| Phase 1/2 | Integrin β7 (active-conformer epitope recognized by the MMG49 antibody)Cell therapy | Multiple Myeloma | |
| Phase 1 | Undisclosed / early pipelineSmall molecule | Major Depressive DisorderSchizophrenia |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.